Literature DB >> 19908114

Impact of main bronchial lymph node involvement in pathological T1-2N1M0 non-small-cell lung cancer: multi-institutional survey by the Japan National Hospital Study Group for Lung Cancer.

Hajime Maeda1, Shimao Fukai, Akihide Matsumura, Osamu Kawashima, Takehiro Watanabe, Takeshi Yamanda, Kan Okabayashi, Yuka Fujita, Atsuhisa Tamura, Masaaki Kawahara.   

Abstract

PURPOSE: According to the TNM classification revised in 1997, stage II non-small-cell lung cancer (NSCLC) has an unfavorable prognosis. The purpose of this study was to analyze the prognostic factors for pathological T1-2N1M0 patients with NSCLC and elucidate the significance of main bronchial lymph nodes involvement.
METHODS: This retrospective study analyzed patients in a prospective database of cases from an 11-year period (operations from 1992 to 2002, follow-up data until March 2008) obtained from the Japan National Hospital Study Group for Lung Cancer. Among them, a total of 319 patients with pathological T1-2N1M0 disease were identified, and all dissected lymph nodes were classified using the Naruke map.
RESULTS: The cumulative overall 5-year survival rate for patients with intralobar or interlobar lymph node involvement (n = 266) was 56.8%, and that for those with main bronchial lymph node involvement (n = 53) was 40.4% (P = 0.002). Among patients with multiple-station N1 nodal involvement including the main bronchial lymph nodes, patients with a lower lobe tumor (n = 12) had a significantly worse prognosis than those with an upper lobe tumor (n = 9) (13.3% vs. 55.6%, P = 0.033). Multivariate analysis demonstrated that age, histology, tumor size, and main bronchial lymph node involvement were independent prognostic factors for patients with pathological T1-2N1M0 disease.
CONCLUSION: Involvement of the main bronchial lymph nodes is a significant factor to predict a worse prognosis in pathological T1-2N1M0 patients with NSCLC.

Entities:  

Mesh:

Year:  2009        PMID: 19908114     DOI: 10.1007/s11748-009-0451-z

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  30 in total

1.  Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival.

Authors:  Toshio Fujimoto; Stephen D Cassivi; Ping Yang; Sunni A Barnes; Francis C Nichols; Claude Deschamps; Mark S Allen; Peter C Pairolero
Journal:  J Thorac Cardiovasc Surg       Date:  2006-07-28       Impact factor: 5.209

2.  Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung.

Authors:  M Riquet; D Manac'h; F Le Pimpec-Barthes; A Dujon; A Chehab
Journal:  Ann Thorac Surg       Date:  1999-06       Impact factor: 4.330

3.  Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials.

Authors:  Y Ichinose; H Kato; T Koike; R Tsuchiya; T Fujisawa; N Shimizu; Y Watanabe; T Mitsudomi; M Yoshimura
Journal:  Lung Cancer       Date:  2001-10       Impact factor: 5.705

4.  Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma.

Authors:  E van Velzen; R J Snijder; A Brutel de la Rivière; H R Elbers; J M van den Bosch
Journal:  Ann Thorac Surg       Date:  1997-05       Impact factor: 4.330

5.  Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes.

Authors:  T Yano; H Yokoyama; T Inoue; H Asoh; K Tayama; Y Ichinose
Journal:  J Thorac Cardiovasc Surg       Date:  1994-06       Impact factor: 5.209

6.  Prognosis of completely resected pN2 non-small cell lung carcinomas: What is the significant node that affects survival?

Authors:  M Okada; N Tsubota; M Yoshimura; Y Miyamoto; H Matsuoka
Journal:  J Thorac Cardiovasc Surg       Date:  1999-08       Impact factor: 5.209

7.  Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.

Authors:  Alain Depierre; Bernard Milleron; Denis Moro-Sibilot; Sylvie Chevret; Elisabeth Quoix; Bernard Lebeau; Denis Braun; Jean-Luc Breton; Etienne Lemarié; Sylvie Gouva; Nadine Paillot; Jeanne-Marie Bréchot; Henri Janicot; François-Xavier Lebas; Philippe Terrioux; Jean Clavier; Pascal Foucher; Michel Monchâtre; Daniel Coëtmeur; Marie-Claude Level; Pascal Leclerc; François Blanchon; Jean-Michel Rodier; Luc Thiberville; Anne Villeneuve; Virginie Westeel; Claude Chastang
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

8.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

9.  Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe.

Authors:  Masayoshi Inoue; Noriyoshi Sawabata; Shin-ichi Takeda; Mitsunori Ohta; Yuko Ohno; Hajime Maeda
Journal:  J Thorac Cardiovasc Surg       Date:  2004-04       Impact factor: 5.209

10.  Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.

Authors:  Steven M Keller; Mark G Vangel; Henry Wagner; Joan H Schiller; Arnold Herskovic; Ritsuko Komaki; Randolph S Marks; Michael C Perry; Robert B Livingston; David H Johnson
Journal:  J Thorac Cardiovasc Surg       Date:  2004-07       Impact factor: 5.209

View more
  1 in total

1.  Prognostic value of different N1 lymph node zones in pN1M0 non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Fengling Hu; Chutong Lin; Hongling Chu; Peng Ren; Jingdi Wang; Shaohua Ma
Journal:  Sci Rep       Date:  2021-11-03       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.